Clin J Am Soc Nephrol. 2007;2:1360–6.PubMedCrossRef

9. Kohro T, Furui Y, Mitsutake N, Fujii R, Morita H, Oku S, et al. The Japanese national health screening and intervention program aimed at preventing worsening of the metabolic syndrome. Int Heart J. 2008;49:193–203.PubMedCrossRef 10. Yamagata K, Iseki K, Nitta K, Imai H, Iino Y, Matsuo S, et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol. 2008;12:1–8.PubMedCrossRef 11. Iseki K. Role of urinalysis in the diagnosis of chronic kidney disease (CKD). JMAJ. 2011;54:27–30. 12. Kondo M, Yamagata K, Hoshi SL, Saito C, Asahi K, Moriyama T, et al. Cost-effectiveness of chronic kidney disease mass screening test in Japan. Clin Exp Nephrol. 2012;16:279–91.PubMedCentralPubMedCrossRef 13. Cohen J, Cairns C, Paquette C, Faden L. Comparing patient access to pharmaceuticals in the UK and US. Appl Health Econ Health www.selleckchem.com/products/AP24534.html AZD5363 order Policy. 2006;5:177–87.PubMedCrossRef 14. Adang E, Voordijk L, Jan van der Wilt G, Ament A. Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions. Health Policy. 2005;74:146–56.PubMedCrossRef 15. Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten

M, et al. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices—budget impact analysis. Value Health. 2007;10:336–47.PubMedCrossRef 16. Li PK, Chow KM, Matsuo S, Yang CW, Jha V, Becker G, et al. Asian chronic kidney disease best practice recommendations: positional statements for early detection of chronic kidney disease from Asian forum for chronic kidney disease initiatives (AFCKDI). Nephrology (Carlton). 2011;16:633–41.PubMed 17. Tsukamoto Y, Wang H, Becker G, Chen HC, Han DS, Harris D, et al. Report of the Asian Forum of Chronic Kidney Disease Initiative (AFCKDI) 2007. Current status and perspective of CKD in Asia: diversity and specificity among Asian countries. Clin Exp Nephrol. 2009; 13:249–56. 18. Seino Y. New diagnostic Terminal deoxynucleotidyl transferase criteria for diabetes in Japan. Nippon Rinsho. 2010;68:2357–61.PubMed

19. Culyer AJ. The dictionary of health economics. 2nd ed. Cheltenham: Edward Elger; 2010.CrossRef 20. National Institute of Population and Social Security Research Tokyo, Japan. Population projections for Japan—a supplement to the 2006 revision—(commentary with ancillary projections). Tokyo: Health and Welfare Statistics Association. 2008. 21. Ministry of Health, Labour and Welfare. Heisei 20 nendo tokutei kenko shinsatokutei hoken shidono jisshi jyokyo ni tsuite. Tokyo: Ministry of Health, Labour and Welfare. 2010. 22. Ministry of Health, Labour and Welfare. Estimates of National Medical Care Expenditure 2010. Tokyo: Ministry of Health, Labour and Welfare. 2013. 23. Nishiyama A, Hitomi H, Rahman A, Kiyomoto H. Drug discovery for overcoming chronic kidney disease (CKD): pharmacological effects of mineralocorticoid-receptor blockers. J Pharmacol Sci.